ITM signs supply deals with Point Biopharma

2016 08 24 09 43 13 537 Hands Shaking V3 400

German radiopharmaceutical group ITM Isotopen Technologien München has signed supply agreements with radiopharmaceutical Point Biopharma for ITM's EndolucinBeta (no-carrier-added lutetium-177) radiopharmaceutical precursor.

The two deals will support the clinical and commercial supply of PNT2002, a radiopharmaceutical candidate for the treatment of metastatic castrate-resistant prostate cancer. The first contract details a partnership for the clinical development of PNT2002, while the second is a long-term commercial agreement for the supply of no-carrier-added lutetium-177 following the marketing approval of PNT2002.

A phase III clinical trial for PNT2002 is expected to begin enrolling patients in the fourth quarter, according to the companies. Further terms of the deals were not disclosed.

Page 1 of 116
Next Page